MedTrace Logo

Expanding the Pool in Lung Transplantation

NCT03377478 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2022-12-16

No results posted yet for this study

Summary

To perform a study (20 patients) utilizing Hepatitis C positive (HCV Ab+/NAT -) donor lungs for hepatitis C negative recipients with post-operative surveillance and treatment only if a recipient infection occurs.

Conditions

  • Hepatitis C
  • Lung Transplant

Interventions

DRUG

Epclusa

Patients testing positive for HCV viremia will receive 12 weeks of Epclusa.

Sponsors & Collaborators

  • Pablo Sanchez

    lead OTHER

Principal Investigators

  • Pablo Sanchez, MD · Assistant Professor of Surgery/University of Pittsburgh

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-07-30
Primary Completion
2021-09-21
Completion
2022-04-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03377478 on ClinicalTrials.gov